(1R)-1-(3-chloro-5-fluorophenyl)ethanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R)-1-(3-chloro-5-fluorophenyl)ethanamine
• 英文别名: (R)-1-(3-Chloro-5-fluorophenyl)ethanamine
• 化学式: C₈H₉ClFN
• 分子量: 173.618
• InChiKey: BVVJDCFVSXSRBB-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1R)-1-(3-chloro-5-fluorophenyl)ethanamine 、 3,4-dichloro-6-[6-(dimethylphosphoryl)pyridin-3-yl]-7-fluoro-2-methyl-1,5-naphthyridine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 [2'-(diphenylphosphanyl)-[1,1'-binaphthalen]-2-yl]diphenylphosphane 、 caesium carbonate 作用下， 以 甲苯 为溶剂， 以23 %的产率得到3-chloro-N-[(1R)-1-(3-chloro-5-fluorophenyl)ethyl]-6-[6-(dimethylphosphoryl)pyridin-3-yl]-7-fluoro-2-methyl-1,5-naphthyridin-4-amine
  参考文献：
  名称：

  [EN] MODULATORS OF TNF-ALPHA ACTIVITY
  [FR] MODULATEURS DE L'ACTIVITÉ DU TNF-ALPHA

  摘要：

  Provided herein are inhibitors of TNF-α, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-α inhibitory compounds for the treatment of diseases or disorders.

  公开号：

  WO2023240253A2

文献信息

• HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Asana BioSciences, LLC

  公开号：EP3842429A1

  公开（公告）日：2021-06-30

  The present application provides a compound that is N-(2-amino-1-(3 -chloro-5 -fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (shown below), or a pharmaceutically acceptable salt or stereoisomer thereof. Also provided are methods for preparing the compound. The compound is useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of the compound, the compouns is effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using the compound and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了一种化合物，即 N-(2-氨基-1-(3-氯-5-氟苯基)乙基)-1-(5-甲基-2-((四氢-2H-吡喃-4-基)氨基)嘧啶-4-基)-1H-咪唑-4-甲酰胺（如下图所示），或其药学上可接受的盐或立体异构体。还提供了制备该化合物的方法。该化合物可用于抑制 ERK1/2。通过向有需要的患者施用治疗有效量的化合物，该化合物可有效治疗与 RAS/RAF/MEK/ERK 通路失调相关的疾病。使用该化合物可以治疗多种疾病，包括以细胞异常增殖为特征的疾病。在一个实施方案中，疾病是癌症。
• SERINE/THREONINE KINASE INHIBITORS
  申请人：Array Biopharma, Inc.

  公开号：EP2681215B1

  公开（公告）日：2015-04-22